Development of a novel human triculture model of non-alcoholic fatty liver disease and identification of berberine as ameliorating steatosis, oxidative stress and fibrosis
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Objectives: Non-alcoholic fatty liver disease (NAFLD) and its progression to non-alcoholic steatohepatitis (NASH) and hepatocarcinoma is a serious and growing problem. However, the development of new therapies is severely hindered by a lack of high-throughput assays for drug testing. Methods: We have developed a simple transwell assay comprised of HepG2 hepatocytes, hepatic LX-2 stellate cells, and differentiated THP-1 cells. The cells were incubated with an activating mixture containing the NASH-associated risk factors, glucose, insulin, free fatty acids (FFAs), and lipopolysaccharide (LPS) for 72 h. We compared different combinations of culture conditions to obtain a model system that recapitulates the main features of NAFLD/NASH, i.e., increased steatosis, reactive oxygen species (ROS), secretion of pro-inflammatory cytokines/chemokines, and presence of fibrosis. To confirm the usefulness of the optimized model system, we screened for compounds that inhibit steatosis in the hepatocytes and evaluated the most effective compound in the triculture model system. Results: The activating mixture stimulated HepG2 cells in this triculture to accumulate more fat and produce higher levels of reactive oxygen species (ROS) than HepG2 cells in monocultures. As well, higher levels of inflammatory cytokines and chemokines (IL-8, IL-6, MIP-1α, etc. ) were produced in this triculture compared to monocultures. In addition, in all LX-2 monocultures and cocultures, exposure to the activating mixture increased markers of fibrosis. A major strength of our triculture system is that it makes possible the simultaneous monitoring of 4 main features of NASH, i.e., steatosis, oxidative stress, inflammation and fibrosis. Screening potential modulators that may reduce steatosis in HepG2 cells revealed the protective effects of the isoalkaloid, berberine. Tested using this novel triculture assay, treatment with 5 µM berberine decreased steatosis and ROS in HepG2 hepatocytes, reduced inflammatory cytokine production and inhibited collagen production from LX-2 cells. Conclusion: This simple triculture model recapitulates the main features of NAFLD/NASH and should be useful for high-throughput preclinical drug discovery. In this model, berberine showed promising results in decreasing steatosis and ROS and protection against fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of an “activating mixture” of several components (FFAs + glucose + insulin + LPS + TGF-β + BSA) simultaneously mimics the metabolic, inflammatory, and profibrogenic risk factors of MASLD, allowing for the reproduction of steatosis, oxidative stress, inflammation, and fibrogenesis within a single experimental system.”
From The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease (2026) · cites this paper as [134]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In more complex systems (3D cultures, co-cultures), lower FFA concentrations (10–500 μM) are required [131,132,133,134], which brings conditions closer to physiological ones and reduces the risk of non-specific cytotoxicity.”
From The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease (2026) · cites this paper as [134]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“MASLD modeling using co-cultures aims to reproduce the tissue microenvironment of the liver, including intercellular interactions between hepatocytes and non-parenchymal cells (stellate, immune), which is a key factor in the progression from steatosis to steatohepatitis and fibrosis [132,133,134].”
From The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease (2026) · cites this paper as [134]
The cited source says what the claim attributes to it.
In the citing paper
“To study the progression of steatosis to steatohepatitis with inflammation and fibrogenesis, a three-cell culture model—such as HepG2 + LX-2 + THP-1 with an activating mixture [134]—represents the most comprehensive solution, simultaneously reproducing steatosis, oxidative stress, inflammation, and fibrosis within a high-throughput system.”
From The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease (2026) · cites this paper as [134]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842 · cited 1×
“…of NAFLD/NASH is a result of the interplay amongst the three major liver-resident cells (hepatocytes, HSCs and activated macrophages), a model system containing representatives of all three cell types would be desirable (Friedman, 2008; Barbero-Becerra et al., 2015; Sanches et al., 2015).”
BackgroundPathogenesis of Liver Fibrosis
Hernandez-Gea, V., & Friedman, S. L. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130246 · Cited by 1,809
Chitturi, S., Abeygunasekera, S., Farrell, G. C., Holmes-Walker, J., Hui, J. M., Fung, C., Karim, R., Lin, R., Samarasinghe, D., Liddle, C., et al. (2002) · Hepatology · doi:10.1053/jhep.2002.30692 · Cited by 1,122
Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis
Xu, L., Hui, A. Y., Albanis, E., Arthur, M. J., O’Byrne, S. M., Blaner, W. S., Mukherjee, P., Friedman, S. L., & Eng, F. J. (2005) · Gut · doi:10.1136/gut.2004.042127 · Cited by 1,014
Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis
Rolo, A. P., Teodoro, J. S., & Palmeira, C. M. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.10.003 · Cited by 955 · cited 1×
“Oxidative stress triggers the production of in fl ammatory cytokines and chemokines, leading to in fl ammation, fi brogenic responses and the progression of NAFLD to NASH (Rolo et al., 2012; Takaki et al., 2013).”
BackgroundNon alcoholic fatty liver disease and metabolic syndrome.
Paschos, P., & Paletas, K. (2009) · PubMed Central · Cited by 718
Molecular pathways of nonalcoholic fatty liver disease development and progression
Bessone, F., Razori, M. V., & Roma, M. G. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2947-0 · Cited by 610
Berberine suppresses proinflammatory responses through AMPK activation in macrophages
Jeong, H. W., Hsu, K. C., Lee, J.-W., Ham, M., Huh, J. Y., Shin, H. J., Kim, W. S., & Kim, J. B. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90599.2008 · Cited by 454
Takaki, A., Kawai, D., & Yamamoto, K. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141020704 · Cited by 447
Organotypic liver culture models: meeting current challenges in toxicity testing
LeCluyse, E. L., Witek, R. P., Andersen, M. E., & Powers, M. J. (2012) · Critical Reviews in Toxicology · doi:10.3109/10408444.2012.682115 · Cited by 363
Non-Alcoholic Fatty Liver Disease and the Metabolic Syndrome
Najjar, S. M. (2011) · Metabolic Basis of Obesity · doi:10.1007/978-1-4419-1607-5_12 · Cited by 354
Hepatic fibrosis: molecular mechanisms and drug targets
Lotersztajn, S., Julien, B., Teixeira-Clerc, F., Grenard, P., & Mallat, A. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095906 · Cited by 325
Sharma, S., Mells, J. E., Fu, P. P., Saxena, N. K., & Anania, F. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025269 · Cited by 272
Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis
Akazawa, Y., Cazanave, S., Mott, J. L., Elmi, N., Bronk, S. F., Kohno, S., Charlton, M. R., & Gores, G. J. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.01.003 · Cited by 252
Plasma total and free fatty acids composition in human non-alcoholic steatohepatitis
TAVARES DE ALMEIDA, I., CORTEZ-PINTO, H., FIDALGO, G., RODRIGUES, D., & CAMILO, M. E. (2002) · Clinical Nutrition · doi:10.1054/clnu.2001.0529 · Cited by 243
Bates, J., Vijayakumar, A., Ghoshal, S., Marchand, B., Yi, S., Kornyeyev, D., Zagorska, A., Hollenback, D., Walker, K., Liu, K., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.037 · Cited by 230
Approach to the Pathogenesis and Treatment of Nonalcoholic Steatohepatitis
Medina, J., Fernández-Salazar, L. I., García-Buey, L., & Moreno-Otero, R. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.2057 · Cited by 229
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease
Yan, H.-M., Xia, M.-F., Wang, Y., Chang, X.-X., Yao, X.-Z., Rao, S.-X., Zeng, M.-S., Tu, Y.-F., Feng, R., Jia, W.-P., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0134172 · Cited by 229
Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy
Ma, J., Zhou, Q., & Li, H. (2017) · Nutrients · doi:10.3390/nu9101124 · Cited by 197
Nonalcoholic steatohepatitis: a search for factual animal models
Sanches, S. C. L., Ramalho, L. N. Z., Augusto, M. J., da Silva, D. M., & Ramalho, F. S. (2015) · BioMed Research International · doi:10.1155/2015/574832 · Cited by 174
Anthérieu, S., Rogue, A., Fromenty, B., Guillouzo, A., & Robin, M.-A. (2011) · Hepatology · doi:10.1002/hep.24290 · Cited by 167
Pathophysiology of NASH: perspectives for a targeted treatment
Marra, F., & Lotersztajn, S. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990344 · Cited by 163
Zhou, J. Y., Zhou, S. W., Zhang, K. B., Tang, J. L., Guang, L. X., Ying, Y., Xu, Y., Zhang, L., & Li, D. D. (2008) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.31.1169 · Cited by 156
Development of an in vitro human liver system for interrogating nonalcoholic steatohepatitis
Feaver, R. E., Cole, B. K., Lawson, M. J., Hoang, S. A., Marukian, S., Blackman, B. R., Figler, R. A., Sanyal, A. J., Wamhoff, B. R., & Dash, A. (2016) · JCI Insight · doi:10.1172/jci.insight.90954 · Cited by 153 · cited 6×
“This increase in intracellular lipids, coupled with oxidative stress and in fl ammation, likely contributes to the development of NASH (Feaver et al., 2016).”
BackgroundResultInfluentialRafiei, H., Omidian, K., & Bandy, B. (2019) · Nutrients · doi:10.3390/nu11030541 · Cited by 137
Self-citationYi, J., Wu, S., Tan, S., Qin, Y., Wang, X., Jiang, J., Liu, H., & Wu, B. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00768-7 · Cited by 133
Recent pharmacological studies on natural products in China
Zhu, X., Li, X., & Liu, J. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.07.027 · Cited by 126
Human in vitro models of nonalcoholic fatty liver disease
Müller, F. A., & Sturla, S. J. (2019) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2019.03.001 · Cited by 118 · cited 1×
“The underlying molecular mechanisms leading to the progression of NAFLD to NASH are complex and multiple factors may work in parallel in the disease process (Müller and Sturla, 2019).”
BackgroundSugimoto, R., Enjoji, M., Kohjima, M., Tsuruta, S., Fukushima, M., Iwao, M., Sonta, T., Kotoh, K., Inoguchi, T., & Nakamuta, M. (2005) · Liver International · doi:10.1111/j.1478-3231.2005.01130.x · Cited by 115
Cooperation of Ito cells and hepatocytes in the deposition of an extracellular matrix in vitro.
Loréal, O., Levavasseur, F., Fromaget, C., Gros, D., Guillouzo, A., & Clément, B. (1993) · PubMed Central · Cited by 110
Zhang, Z., Li, B., Meng, X.-J., Yao, S., Jin, L., Yang, J., Wang, J., Zhang, H., Zhang, Z., Cai, D., et al. (2016) · Scientific Reports · doi:10.1038/srep20848 · Cited by 107
Zhang, J., Zhang, S.-D., Wang, P., Guo, N., Wang, W., Yao, L., Yang, Q., Efferth, T., Jiao, J., & Fu, Y. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172618 · Cited by 95
Wei, X., Wang, C., Hao, S., Song, H., & Yang, L. (2016) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2016/3593951 · Cited by 88
García-Ruiz, I., Solís-Muñoz, P., Fernández-Moreira, D., Muñoz-Yagüe, T., & Solís-Herruzo, J. A. (2014) · Disease Models & Mechanisms · doi:10.1242/dmm.018234 · Cited by 83
Sun, Y., Wang, J., Guo, X., Zhu, N., Niu, L., Ding, X. D., Xie, Z., Chen, X., & Yang, F. (2021) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2019.06.005 · Cited by 80
Non-alcoholic fatty liver disease (NAFLD) models in drug discovery
Cole, B. K., Feaver, R. E., Wamhoff, B. R., & Dash, A. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1410135 · Cited by 79
Michaut, A., Le Guillou, D., Moreau, C., Bucher, S., McGill, M. R., Martinais, S., Gicquel, T., Morel, I., Robin, M.-A., Jaeschke, H., et al. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2015.12.020 · Cited by 73
The interplay between hepatic stellate cells and hepatocytes in an in vitro model of NASH
Barbero-Becerra, V. J., Giraudi, P. J., Chávez-Tapia, N. C., Uribe, M., Tiribelli, C., & Rosso, N. (2015) · Toxicology in Vitro · doi:10.1016/j.tiv.2015.07.010 · Cited by 71
Luo, Y., Tian, G., Zhuang, Z., Chen, J., You, N., Zhuo, L., Liang, B., Song, Y., Zang, S., Liu, J., et al. (2019) · PubMed · Cited by 70
The Potential Mechanisms of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease
Zhu, X., Bian, H., & Gao, X. (2016) · Molecules · doi:10.3390/molecules21101336 · Cited by 62
Berberine Inhibits Hepatic Stellate Cell Proliferation and Prevents Experimental Liver Fibrosis
Sun, X., Zhang, X., Hu, H., Lu, Y., Chen, J., Yasuda, K., & Wang, H. (2009) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.32.1533 · Cited by 61
Suurmond, C. E., Lasli, S., van den Dolder, F. W., Ung, A., Kim, H., Bandaru, P., Lee, K., Cho, H., Ahadian, S., Ashammakhi, N., et al. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201901379 · Cited by 61
Rafiei, H., Omidian, K., & Bandy, B. (2017) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201600781 · Cited by 55
Self-citationLiu, X., Wang, L., Tan, S., Chen, Z., Wu, B., & Wu, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.814871 · Cited by 54
Chen, Y., & Ma, K. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.02.099 · Cited by 53
Aqueous Extract of Dried Fruit ofBerberis vulgaris L.in Acne vulgaris, a Clinical Trial
Fouladi, R. F. (2012) · Journal of Dietary Supplements · doi:10.3109/19390211.2012.726702 · Cited by 44
Rafiei, H., Omidian, K., & Bandy, B. (2018) · Journal of Functional Foods · doi:10.1016/j.jff.2018.02.033 · Cited by 26
Self-citationCui, H.-S., Hayasaka, S., Zheng, L., Hayasaka, Y., Zhang, X.-Y., & Chi, Z. (2006) · Ophthalmic Research · doi:10.1159/000097904 · Cited by 20
Rafiei, H., Omidian, K., & Bandy, B. (2019) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b02367 · Cited by 17
Self-citationMarcheluzzo, S., Faggian, M., Zancato, M., & Peron, G. (2021) · Molecules · doi:10.3390/molecules26082222 · Cited by 13
Kobayashi, K., Yoshioka, T., Miyauchi, J., Nakazawa, A., Kiyokawa, N., Maihara, T., & Usami, I. (2018) · Hepatology Communications · doi:10.1002/hep4.1150 · Cited by 10
Cited by
Leslie, J., Krishnamurthy, K. A., Gopalsamy, I. K., Inácio, P., Huch, M., Gallage, S., Oakley, F., & Vacca, M. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01162-9 · Cited by 30
Liu, D., Zhao, H., Zhang, Y., Hu, J., & Xu, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1572197 · Cited by 24
Radu, F. I., Patoni, C., Nancoff, A.-S., Marin, F.-S., Gaman, L. E., Bucurica, A., Socol, C., Jinga, M., Duţu, M., & Bucurica, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084201 · Cited by 21
The Application of Berberine in Fibrosis and the Related Diseases
Gao, R., Lu, Y., Zhang, W., & Zhang, Z. (2024) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x24500307 · Cited by 13
Cheng, C., Liu, X., & Deng, B. (2024) · Current Medical Science · doi:10.1007/s11596-024-2914-y · Cited by 19
Metadata
- Authors
- Rafiei, H., Yeung, M., Kowalski, S., Krystal, G., & Elisia, I.
- Affiliations
- BC Cancer Agency (CA)
- Corresponding author
- Elisia, Ingrid
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2023-10-19
- Volume
- 14
- Pages
- 1234300-1234300
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC10620695
- OpenAlex
- W4387779215
- Cited by
- 21
- References
- 55
- Citations by year
- 2026: 8 · 2025: 5 · 2024: 8
- FWCI
- 4.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Lotte and John Hecht Memorial Foundation (3693)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Pharmacology (medical) › Berberine and alkaloids research
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, berberine, steatosis, oxidative stress, liver fibrosis, hepatic stellate cells, THP-1 macrophages, HepG2 cells, inflammatory cytokines, high-throughput drug screening, collagen synthesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.